Lilly Signs Major Collaboration With Hanmi For RA Drug
This article was originally published in PharmAsia News
Lilly is building out its autoimmune pipeline through a licensing deal with Hanmi that could be worth $690 million to the Korean firm and is indicative of the growing attractiveness of innovation in the Asian country.
You may also be interested in...
Hanmi Pharmaceutical shares fell sharply on the news Lilly has halted Phase II trials of the South Korean firm’s BTK inhibitor for rheumatoid arthritis. But Hanmi says its license contract remains intact and that the two firms are discussing the potential development of the molecule for other indications.
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.